Tumour budding and its clinical implications in gastrointestinal cancers

Abstract

Tumour budding in colorectal cancer has become an important prognostic factor. Represented by single cells or small tumour cell clusters at the invasion front of the tumour mass, these tumour buds seem to reflect cells in a ‘hybrid’ state of epithelial–mesenchymal transition, and evidence indicates that the presence of these entities is associated with lymph node metastasis, local recurrence and distant metastatic disease. The International Tumour Budding Consensus Conference (ITBCC) has highlighted a scoring system for the reporting of tumour budding in colorectal cancer, as well as different clinical scenarios that could affect patient management. Other organs are not spared: tumour budding has been described in numerous gastrointestinal and non-gastrointestinal cancers. Here, we give an update on ITBCC validation studies in the context of colorectal cancer and the clinical implications of tumour budding throughout the upper gastrointestinal and pancreatico-biliary tract.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Tumour budding (visualised by arrows) in different gastrointestinal cancers.

References

  1. 1.

    Lugli, A., Kirsch, R., Ajioka, Y., Bosman, F., Cathomas, G., Dawson, H. et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod. Pathol. 30, 1299–1311 (2017).

    PubMed  Google Scholar 

  2. 2.

    Berg, K. B. & Schaeffer, D. F. Tumor budding as a standardized parameter in gastrointestinal carcinomas: more than just the colon. Mod. Pathol. 31, 862–872 (2018).

    PubMed  Google Scholar 

  3. 3.

    De Smedt, L., Palmans, S., Andel, D., Govaere, O., Boeckx, B., Smeets, D. et al. Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching. Br. J. Cancer 116, 58–65 (2017).

    PubMed  Google Scholar 

  4. 4.

    Davison, J. M., Landau, M. S., Luketich, J. D., McGrath, K. M., Foxwell, T. J., Landsittel, D. P. et al. A model based on pathologic features of superficial esophageal adenocarcinoma complements clinical node staging in determining risk of metastasis to lymph nodes. Clin. Gastroenterol. Hepatol. 14, 369–77 e3 (2016).

    PubMed  Google Scholar 

  5. 5.

    Almangush, A., Karhunen, M., Hautaniemi, S., Salo, T. & Leivo, I. Prognostic value of tumour budding in oesophageal cancer: a meta-analysis. Histopathology 68, 173–182 (2016).

    PubMed  Google Scholar 

  6. 6.

    Thies, S., Guldener, L., Slotta-Huspenina, J., Zlobec, I., Koelzer, V. H., Lugli, A. et al. Impact of peritumoral and intratumoral budding in esophageal adenocarcinomas. Hum. Pathol. 52, 1–8 (2016).

    PubMed  Google Scholar 

  7. 7.

    Guo, Y. X., Zhang, Z. Z., Zhao, G. & Zhao, E. H. Prognostic and pathological impact of tumor budding in gastric cancer: a systematic review and meta-analysis. World J. Gastrointest. Oncol. 11, 898–908 (2019).

    PubMed  PubMed Central  Google Scholar 

  8. 8.

    Gulluoglu, M., Yegen, G., Ozluk, Y., Keskin, M., Dogan, S., Gundogdu, G. et al. Tumor budding is independently predictive for lymph node involvement in early gastric cancer. Int J. Surg. Pathol. 23, 349–358 (2015).

    CAS  PubMed  Google Scholar 

  9. 9.

    Karamitopoulou, E., Wartenberg, M., Zlobec, I., Cibin, S., Worni, M., Gloor, B. et al. Tumour budding in pancreatic cancer revisited: validation of the ITBCC scoring system. Histopathology 73, 137–146 (2018).

    PubMed  Google Scholar 

  10. 10.

    Tanaka, M., Yamauchi, N., Ushiku, T., Shibahara, J., Hayashi, A., Misumi, K. et al. Tumor budding in intrahepatic cholangiocarcinoma: a predictor of postsurgery outcomes. Am. J. Surg. Pathol. 43, 1180–1190 (2019).

    PubMed  Google Scholar 

  11. 11.

    Ho, Y. Y., Wu, T. Y., Cheng, H. C., Yang, C. C. & Wu, C. H. The significance of tumor budding in oral cancer survival and its relevance to theeighth edition of the American Joint Committee on Cancer staging system. Head Neck 41, 2991–3001 (2019).

    PubMed  Google Scholar 

  12. 12.

    Neppl, C., Zlobec, I., Schmid, R. A. & Berezowska, S. Validation of the International Tumor Budding Consensus Conference (ITBCC) 2016 recommendation in squamous cell carcinoma of the lung-a single-center analysis of 354 cases. Mod. Pathol. 33, 802–811 (2020).

    CAS  PubMed  Google Scholar 

  13. 13.

    Kadota, K., Yeh, Y. C., Villena-Vargas, J., Cherkassky, L., Drill, E. N., Sima, C. S. et al. Tumor budding correlates with the protumor immune microenvironment and is an independent prognostic factor for recurrence of stage I lung adenocarcinoma. Chest 148, 711–721 (2015).

    PubMed  PubMed Central  Google Scholar 

  14. 14.

    Li, X., Wei, B., Sonmez, C., Li, Z. & Peng, L. High tumor budding count is associated with adverse clinicopathologic features and poor prognosis in breast carcinoma. Hum. Pathol. 66, 222–229 (2017).

    PubMed  Google Scholar 

  15. 15.

    Jesinghaus, M., Strehl, J., Boxberg, M., Bruhl, F., Wenzel, A., Konukiewitz, B. et al. Introducing a novel highly prognostic grading scheme based on tumour budding and cell nest size for squamous cell carcinoma of the uterine cervix. J. Pathol. Clin. Res. 4, 93–102 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  16. 16.

    Meyer, S. N., Galvan, J. A., Zahnd, S., Sokol, L., Dawson, H., Lugli, A. et al. Co-expression of cytokeratin and vimentin in colorectal cancer highlights a subset of tumor buds and an atypical cancer-associated stroma. Hum. Pathol. 87, 18–27 (2019).

    CAS  PubMed  Google Scholar 

  17. 17.

    Grigore, A. D., Jolly, M. K., Jia, D., Farach-Carson, M. C. & Levine, H. Tumor budding: the name is EMT. Partial EMT. J. Clin. Med. 5, 51 (2016).

    PubMed Central  Google Scholar 

  18. 18.

    Maffeis, V., Nicole, L. & Cappellesso, R. RAS, cellular plasticity, and tumor budding in colorectal cancer. Front Oncol. 9, 1255 (2019).

    PubMed  PubMed Central  Google Scholar 

  19. 19.

    Steinbichler, T. B., Savic, D., Dudas, J., Kvitsaridze, I., Skvortsov, S., Riechelmann, H. et al. Cancer stem cells and their unique role in metastatic spread. Semin Cancer Biol. 60, 148–156 (2020).

    CAS  PubMed  Google Scholar 

  20. 20.

    Jager, T., Neureiter, D., Fallaha, M., Schredl, P., Kiesslich, T., Urbas, R. et al. The potential predictive value of tumor budding for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer. Strahlenther. Onkol. 194, 991–1006 (2018).

    PubMed  PubMed Central  Google Scholar 

  21. 21.

    Miyata, H., Yoshioka, A., Yamasaki, M., Nushijima, Y., Takiguchi, S., Fujiwara, Y. et al. Tumor budding in tumor invasive front predicts prognosis and survival of patients with esophageal squamous cell carcinomas receiving neoadjuvant chemotherapy. Cancer 115, 3324–3334 (2009).

    PubMed  Google Scholar 

  22. 22.

    Centeno, I., Paasinen Sohns, A., Flury, M., Galvan, J. A., Zahnd, S., Koelzer, V. H. et al. DNA profiling of tumor buds in colorectal cancer indicates that they have the same mutation profile as the tumor from which they derive. Virchows Arch. 470, 341–346 (2017).

    PubMed  Google Scholar 

  23. 23.

    Jensen, D. H., Dabelsteen, E., Specht, L., Fiehn, A. M., Therkildsen, M. H., Jonson, L. et al. Molecular profiling of tumour budding implicates TGFbeta-mediated epithelial-mesenchymal transition as a therapeutic target in oral squamous cell carcinoma. J. Pathol. 236, 505–516 (2015).

    CAS  PubMed  Google Scholar 

  24. 24.

    Broders, A. C. Squamous-cell epithelioma of the lip. A study of five hundred and thirty-seven cases. J. Am. Med. Assoc. 74, 656–664 (1920).

    Google Scholar 

  25. 25.

    Watanabe, T., Muro, K., Ajioka, Y., Hashiguchi, Y., Ito, Y., Saito, Y. et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J. Clin. Oncol. 23, 1–34 (2018).

    PubMed  Google Scholar 

  26. 26.

    Ulase, D., Heckl, S., Behrens, H. M., Kruger, S. & Rocken, C. Prognostic significance of tumour budding assessed in gastric carcinoma according to the criteria of the International Tumour Budding Consensus Conference. Histopathology 76, 433–446 (2020).

    PubMed  Google Scholar 

  27. 27.

    Petrova, E., Zielinski, V., Bolm, L., Schreiber, C., Knief, J., Thorns, C. et al. Tumor budding as a prognostic factor in pancreatic ductal adenocarcinoma. Virchows Arch. 476, 561–568 (2020).

    CAS  PubMed  Google Scholar 

  28. 28.

    Pritchard, C. C. & Grady, W. M. Colorectal cancer molecular biology moves into clinical practice. Gut 60, 116–129 (2011).

    CAS  PubMed  Google Scholar 

  29. 29.

    Rogers, A. C., Winter, D. C., Heeney, A., Gibbons, D., Lugli, A., Puppa, G. et al. Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer. Br. J. Cancer 115, 831–840 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  30. 30.

    Cho, S. J. & Kakar, S. Tumor budding in colorectal carcinoma: translating a morphologic score into clinically meaningful results. Arch. Pathol. Lab Med. 142, 952–957 (2018).

    PubMed  Google Scholar 

  31. 31.

    Ueno, H., Mochizuki, H., Hashiguchi, Y., Shimazaki, H., Aida, S., Hase, K. et al. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 127, 385–394 (2004).

    PubMed  Google Scholar 

  32. 32.

    Bosch, S. L., Teerenstra, S., de Wilt, J. H., Cunningham, C. & Nagtegaal, I. D. Predicting lymph node metastasis in pT1 colorectal cancer: a systematic review of risk factors providing rationale for therapy decisions. Endoscopy 45, 827–834 (2013).

    PubMed  Google Scholar 

  33. 33.

    Cappellesso, R., Luchini, C., Veronese, N., Lo Mele, M., Rosa-Rizzotto, E., Guido, E. et al. Tumor budding as a risk factor for nodal metastasis in pT1 colorectal cancers: a meta-analysis. Hum. Pathol. 65, 62–70 (2017).

    CAS  PubMed  Google Scholar 

  34. 34.

    van de Velde, C. J., Boelens, P. G., Borras, J. M., Coebergh, J. W., Cervantes, A., Blomqvist, L. et al. EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. Eur. J. Cancer 50, 1 e–e34 (2014).

    Google Scholar 

  35. 35.

    Schmoll, H. J., Van Cutsem, E., Stein, A., Valentini, V., Glimelius, B., Haustermans, K. et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann. Oncol. 23, 2479–2516 (2012).

    CAS  PubMed  Google Scholar 

  36. 36.

    Betge, J., Kornprat, P., Pollheimer, M. J., Lindtner, R. A., Schlemmer, A., Rehak, P. et al. Tumor budding is an independent predictor of outcome in AJCC/UICC stage II colorectal cancer. Ann. Surg. Oncol. 19, 3706–3712 (2012).

    PubMed  Google Scholar 

  37. 37.

    Canney, A. L., Kevans, D., Wang, L. M., Hyland, J. M., Mulcahy, H. E., O'Donoghue, D. P. et al. Stage II colonic adenocarcinoma: a detailed study of pT4N0 with emphasis on peritoneal involvement and the role of tumour budding. Histopathology 61, 488–496 (2012).

    PubMed  Google Scholar 

  38. 38.

    Petrelli, F., Pezzica, E., Cabiddu, M., Coinu, A., Borgonovo, K., Ghilardi, M. et al. Tumour budding and survival in stage II colorectal cancer: a systematic review and pooled analysis. J. Gastrointest. Cancer 46, 212–218 (2015).

    CAS  PubMed  Google Scholar 

  39. 39.

    Lai, Y. H., Wu, L. C., Li, P. S., Wu, W. H., Yang, S. B., Xia, P. et al. Tumour budding is a reproducible index for risk stratification of patients with stage II colon cancer. Colorectal Dis. 16, 259–264 (2014).

    PubMed  Google Scholar 

  40. 40.

    Nakamura, T., Mitomi, H., Kanazawa, H., Ohkura, Y. & Watanabe, M. Tumor budding as an index to identify high-risk patients with stage II colon cancer. Dis. Colon Rectum 51, 568–572 (2008).

    PubMed  Google Scholar 

  41. 41.

    Hayes, B. D., Maguire, A., Conlon, N., Gibbons, D., Wang, L. M. & Sheahan, K. Reproducibility of the rapid bud count method for assessment of tumor budding in stage II colorectal cancer. Am. J. Surg. Pathol. 34, 746–748 (2010).

    PubMed  Google Scholar 

  42. 42.

    Okuyama, T., Nakamura, T. & Yamaguchi, M. Budding is useful to select high-risk patients in stage II well-differentiated or moderately differentiated colon adenocarcinoma. Dis. Colon Rectum 46, 1400–1406 (2003).

    PubMed  Google Scholar 

  43. 43.

    Okuyama, T., Oya, M. & Ishikawa, H. Budding as a risk factor for lymph node metastasis in pT1 or pT2 well-differentiated colorectal adenocarcinoma. Dis. Colon Rectum 45, 628–634 (2002).

    PubMed  Google Scholar 

  44. 44.

    Okuyama, T., Oya, M. & Ishikawa, H. Budding as a useful prognostic marker in pT3 well- or moderately-differentiated rectal adenocarcinoma. J. Surg. Oncol. 83, 42–47 (2003).

    PubMed  Google Scholar 

  45. 45.

    WHO Classification of Tumours Editorial Board. Digestive System Tumours, Fifth edn. (IARC, Lyon, France, 2019).

  46. 46.

    Ueno, H., Ishiguro, M., Nakatani, E., Ishikawa, T., Uetake, H., Matsuda, C. et al. Prospective multicenter study on the prognostic and predictive impact of tumor budding in stage II colon cancer: results from the SACURA trial. J. Clin. Oncol. 37, 1886–1894 (2019).

    CAS  PubMed  Google Scholar 

  47. 47.

    Morodomi, T., Isomoto, H., Shirouzu, K., Kakegawa, K., Irie, K. & Morimatsu, M. An index for estimating the probability of lymph node metastasis in rectal cancers. Lymph node metastasis and the histopathology of actively invasive regions of cancer. Cancer 63, 539–543 (1989).

    CAS  PubMed  Google Scholar 

  48. 48.

    Lugli, A., Vlajnic, T., Giger, O., Karamitopoulou, E., Patsouris, E. S., Peros, G. et al. Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patients. Hum. Pathol. 42, 1833–1840 (2011).

    PubMed  Google Scholar 

  49. 49.

    Zlobec, I., Hadrich, M., Dawson, H., Koelzer, V. H., Borner, M., Mallaev, M. et al. Intratumoural budding (ITB) in preoperative biopsies predicts the presence of lymph node and distant metastases in colon and rectal cancer patients. Br. J. Cancer 110, 1008–1013 (2014).

    CAS  PubMed  Google Scholar 

  50. 50.

    Rogers, A. C., Gibbons, D., Hanly, A. M., Hyland, J. M., O'Connell, P. R., Winter, D. C. et al. Prognostic significance of tumor budding in rectal cancer biopsies before neoadjuvant therapy. Mod. Pathol. 27, 156–162 (2014).

    PubMed  Google Scholar 

  51. 51.

    Giger, O. T., Comtesse, S. C., Lugli, A., Zlobec, I. & Kurrer, M. O. Intra-tumoral budding in preoperative biopsy specimens predicts lymph node and distant metastasis in patients with colorectal cancer. Mod. Pathol. 25, 1048–1053 (2012).

    PubMed  Google Scholar 

  52. 52.

    Lino-Silva, L. S., Gamboa-Dominguez, A., Zuniga-Tamayo, D., Salcedo-Hernandez, R. A., Cetina, L. & Cantu-de-Leon, D. Mismatch repair protein expression and intratumoral budding in rectal cancer are associated with an increased pathological complete response to preoperative chemoradiotherapy: a case-control study. World J. Clin. Oncol. 9, 133–139 (2018).

    PubMed  PubMed Central  Google Scholar 

  53. 53.

    Marx, A. H., Mickler, C., Sauter, G., Simon, R., Terracciano, L. M., Izbicki, J. R. et al. High-grade intratumoral tumor budding is a predictor for lymphovascular invasion and adverse outcome in stage II colorectal cancer. Int. J. Colorectal Dis. 35, 259–268 (2020).

    PubMed  Google Scholar 

  54. 54.

    Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol. 27, 1386–1422 (2016).

    PubMed  Google Scholar 

  55. 55.

    Rubbia-Brandt, L., Giostra, E., Brezault, C., Roth, A. D., Andres, A., Audard, V. et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann. Oncol. 18, 299–304 (2007).

    CAS  PubMed  Google Scholar 

  56. 56.

    Van den Eynden, G. G., van Dam, P. J., Stroobants, S., Dirix, L., Vermeulen, P. & Liver Metastasis Research, N. Histopathological evaluation of resected colorectal cancer liver metastases: what should be done? Histopathology 64, 315–316 (2014).

    PubMed  Google Scholar 

  57. 57.

    Van den Eynden, G. G., Majeed, A. W., Illemann, M., Vermeulen, P. B., Bird, N. C., Hoyer-Hansen, G. et al. The multifaceted role of the microenvironment in liver metastasis: biology and clinical implications. Cancer Res. 73, 2031–2043 (2013).

    PubMed  Google Scholar 

  58. 58.

    Van den Eynden, G. G., Bird, N. C., Majeed, A. W., Van Laere, S., Dirix, L. Y. & Vermeulen, P. B. The histological growth pattern of colorectal cancer liver metastases has prognostic value. Clin. Exp. Metastasis. 29, 541–549 (2012).

    PubMed  Google Scholar 

  59. 59.

    Lazaris, A., Amri, A., Petrillo, S. K., Zoroquiain, P., Ibrahim, N., Salman, A. et al. Vascularization of colorectal carcinoma liver metastasis: insight into stratification of patients for anti-angiogenic therapies. J. Pathol. Clin. Res. 4, 184–192 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  60. 60.

    Frentzas, S., Simoneau, E., Bridgeman, V. L., Vermeulen, P. B., Foo, S., Kostaras, E. et al. Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. Nat. Med. 22, 1294–1302 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  61. 61.

    Eefsen, R. L., Vermeulen, P. B., Christensen, I. J., Laerum, O. D., Mogensen, M. B., Rolff, H. C. et al. Growth pattern of colorectal liver metastasis as a marker of recurrence risk. Clin. Exp. Metastasis. 32, 369–381 (2015).

    CAS  PubMed  Google Scholar 

  62. 62.

    van Dam, P. J., van der Stok, E. P., Teuwen, L. A., Van den Eynden, G. G., Illemann, M., Frentzas, S. et al. International consensus guidelines for scoring the histopathological growth patterns of liver metastasis. Br. J. Cancer 117, 1427–1441 (2017).

    PubMed  PubMed Central  Google Scholar 

  63. 63.

    Blank, A., Schenker, C., Dawson, H., Beldi, G., Zlobec, I. & Lugli, A. Evaluation of tumor budding in primary colorectal cancer and corresponding liver metastases based on H&E and pancytokeratin staining. Front Med. 6, 247 (2019).

    Google Scholar 

  64. 64.

    Fonseca, G. M., de Mello, E. S., Faraj, S. F., Kruger, J. A. P., Coelho, F. F., Jeismann, V. B. et al. Prognostic significance of poorly differentiated clusters and tumor budding in colorectal liver metastases. J. Surg. Oncol. 117, 1364–1375 (2018).

    CAS  PubMed  Google Scholar 

  65. 65.

    Roh, M. S., Lee, J. I. & Choi, P. J. Tumor budding as a useful prognostic marker in esophageal squamous cell carcinoma. Dis. Esophagus 17, 333–337 (2004).

    CAS  PubMed  Google Scholar 

  66. 66.

    Koike, M., Kodera, Y., Itoh, Y., Nakayama, G., Fujiwara, M., Hamajima, N. et al. Multivariate analysis of the pathologic features of esophageal squamous cell cancer: tumor budding is a significant independent prognostic factor. Ann. Surg. Oncol. 15, 1977–1982 (2008).

    PubMed  Google Scholar 

  67. 67.

    Teramoto, H., Koike, M., Tanaka, C., Yamada, S., Nakayama, G., Fujii, T. et al. Tumor budding as a useful prognostic marker in T1-stage squamous cell carcinoma of the esophagus. J. Surg. Oncol. 108, 42–46 (2013).

    PubMed  PubMed Central  Google Scholar 

  68. 68.

    Jesinghaus, M., Boxberg, M., Konukiewitz, B., Slotta-Huspenina, J., Schlitter, A. M., Steiger, K. et al. A novel grading system based on tumor budding and cell nest size is a strong predictor of patient outcome in esophageal squamous cell carcinoma. Am. J. Surg. Pathol. 41, 1112–1120 (2017).

    PubMed  Google Scholar 

  69. 69.

    Jesinghaus, M., Bruhl, F., Steiger, K., Klare, P., Reiser, M., Scheiter, A. et al. Cellular dissociation grading based on the parameters tumor budding and cell nest size in pretherapeutic biopsy specimens allows for prognostic patient stratification in esophageal squamous cell carcinoma independent from clinical staging. Am. J. Surg. Pathol. 43, 618–627 (2019).

    PubMed  Google Scholar 

  70. 70.

    Niwa, Y., Yamada, S., Koike, M., Kanda, M., Fujii, T., Nakayama, G. et al. Epithelial to mesenchymal transition correlates with tumor budding and predicts prognosis in esophageal squamous cell carcinoma. J. Surg. Oncol. 110, 764–769 (2014).

    CAS  PubMed  Google Scholar 

  71. 71.

    Ito, E., Ozawa, S., Kijima, H., Kazuno, A., Nishi, T., Chino, O. et al. New invasive patterns as a prognostic factor for superficial esophageal cancer. J. Gastroenterol. 47, 1279–1289 (2012).

    PubMed  Google Scholar 

  72. 72.

    Nakanishi, Y., Ohara, M., Doumen, H., Kimura, N., Ishidate, T. & Kondo, S. Correlation between tumor budding and post-resection prognosis in patients with invasive squamous cell carcinoma of the thoracic esophagus. World J. Surg. 35, 349–356 (2011).

    PubMed  Google Scholar 

  73. 73.

    Koelzer, V. H., Langer, R., Zlobec, I. & Lugli, A. Tumor budding in upper gastrointestinal carcinomas. Front. Oncol. 4, 216 (2014).

    PubMed  PubMed Central  Google Scholar 

  74. 74.

    Fuchinoue, K., Nemoto, T., Shimada, H., Tochigi, N., Igarashi, Y., Yajima, S. et al. Immunohistochemical analysis of tumor budding as predictor of lymph node metastasis from superficial esophageal squamous cell carcinoma. Esophagus 17, 168–174 (2020).

    PubMed  Google Scholar 

  75. 75.

    Landau, M. S., Hastings, S. M., Foxwell, T. J., Luketich, J. D., Nason, K. S. & Davison, J. M. Tumor budding is associated with an increased risk of lymph node metastasis and poor prognosis in superficial esophageal adenocarcinoma. Mod. Pathol. 27, 1578–1589 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  76. 76.

    Kemi, N., Eskuri, M., Ikalainen, J., Karttunen, T. J. & Kauppila, J. H. Tumor budding and prognosis in gastric adenocarcinoma. Am. J. Surg. Pathol. 43, 229–234 (2019).

    PubMed  Google Scholar 

  77. 77.

    Du, M., Chen, L., Cheng, Y., Wang, Y., Fan, X., Zhang, Y. et al. Tumor budding and other risk factors of lymph node metastasis in submucosal early gastric carcinoma: a multicenter clinicopathologic study in 621 radical gastrectomies of Chinese patients. Am. J. Surg. Pathol. 43, 1074–1082 (2019).

    PubMed  Google Scholar 

  78. 78.

    Shaib, Y. & El-Serag, H. B. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 24, 115–125 (2004).

    PubMed  Google Scholar 

  79. 79.

    Khan, S. A., Toledano, M. B. & Taylor-Robinson, S. D. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB 10, 77–82 (2008).

    CAS  PubMed  PubMed Central  Google Scholar 

  80. 80.

    Rea, D. J., Munoz-Juarez, M., Farnell, M. B., Donohue, J. H., Que, F. G., Crownhart, B. et al. Major hepatic resection for hilar cholangiocarcinoma: analysis of 46 patients. Arch. Surg. 139, 514–523 (2004).

    PubMed  Google Scholar 

  81. 81.

    Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 362, 1273–1281 (2010).

    CAS  PubMed  Google Scholar 

  82. 82.

    Dawson, H., Galuppini, F., Trager, P., Berger, M. D., Studer, P., Brugger, L. et al. Validation of the International Tumor Budding Consensus Conference 2016 recommendations on tumor budding in stage I-IV colorectal cancer. Hum. Pathol. 85, 145–151 (2019).

    PubMed  Google Scholar 

  83. 83.

    Ogino, M., Nakanishi, Y., Mitsuhashi, T., Hatanaka, Y., Amano, T., Marukawa, K. et al. Impact of tumour budding grade in 310 patients who underwent surgical resection for extrahepatic cholangiocarcinoma. Histopathology 74, 861–872 (2019).

    PubMed  Google Scholar 

  84. 84.

    Okubo, S., Mitsunaga, S., Kato, Y., Kojima, M., Sugimoto, M., Gotohda, N. et al. The prognostic impact of differentiation at the invasive front of biliary tract cancer. J. Surg. Oncol. 117, 1278–1287 (2018).

    PubMed  Google Scholar 

  85. 85.

    Primrose, J. N., Fox, R. P., Palmer, D. H., Malik, H. Z., Prasad, R., Mirza, D. et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 20, 663–673 (2019).

    CAS  PubMed  Google Scholar 

  86. 86.

    Shroff, R. T., Kennedy, E. B., Bachini, M., Bekaii-Saab, T., Crane, C., Edeline, J. et al. Adjuvant therapy for resected biliary tract cancer: ASCO Clinical Practice Guideline. J. Clin. Oncol. 37, 1015–1027 (2019).

    PubMed  Google Scholar 

  87. 87.

    Ducreux, M., Cuhna, A. S., Caramella, C., Hollebecque, A., Burtin, P., Goere, D. et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 26(Suppl 5), v56–v68 (2015).

    PubMed  Google Scholar 

  88. 88.

    Lawlor, R. T., Veronese, N., Nottegar, A., Malleo, G., Smith, L., Demurtas, J. et al. Prognostic role of high-grade tumor budding in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis with a focus on epithelial to mesenchymal transition. Cancers (Basel). 11, 113 (2019).

    PubMed Central  Google Scholar 

  89. 89.

    Neoptolemos, J. P., Palmer, D. H., Ghaneh, P., Psarelli, E. E., Valle, J. W., Halloran, C. M. et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 389, 1011–1024 (2017).

    CAS  PubMed  Google Scholar 

  90. 90.

    Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J. L. et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N. Engl. J. Med. 379, 2395–2406 (2018).

    CAS  PubMed  Google Scholar 

  91. 91.

    Lohneis, P., Sinn, M., Klein, F., Bischoff, S., Striefler, J. K., Wislocka, L. et al. Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma. Br. J. Cancer 118, 1485–1491 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  92. 92.

    Almangush, A., Pirinen, M., Heikkinen, I., Makitie, A. A., Salo, T. & Leivo, I. Tumour budding in oral squamous cell carcinoma: a meta-analysis. Br. J. Cancer 118, 577–586 (2018).

    PubMed  Google Scholar 

  93. 93.

    Kai, K., Aishima, S., Aoki, S., Takase, Y., Uchihashi, K., Masuda, M. et al. Cytokeratin immunohistochemistry improves interobserver variability between unskilled pathologists in the evaluation of tumor budding in T1 colorectal cancer. Pathol. Int. 66, 75–82 (2016).

    CAS  PubMed  Google Scholar 

  94. 94.

    Martin, B., Schafer, E., Jakubowicz, E., Mayr, P., Ihringer, R., Anthuber, M. et al. Interobserver variability in the H&E-based assessment of tumor budding in pT3/4 colon cancer: does it affect the prognostic relevance? Virchows Arch. 473, 189–197 (2018).

    PubMed  Google Scholar 

  95. 95.

    Bokhorst, J. M., Blank, A., Lugli, A., Zlobec, I., Dawson, H., Vieth, M. et al. Assessment of individual tumor buds using keratin immunohistochemistry: moderate interobserver agreement suggests a role for machine learning. Mod. Pathol. 33, 825–833 (2020).

    CAS  PubMed  Google Scholar 

  96. 96.

    Fauzi, M. F. A., Chen, W., Knight, D., Hampel, H., Frankel, W. L. & Gurcan, M. N. Tumor budding detection system in whole slide pathology images. J. Med Syst. 44, 38 (2019).

    PubMed  Google Scholar 

  97. 97.

    Lugli, A., Karamitopoulou, E. & Zlobec, I. Tumour budding: a promising parameter in colorectal cancer. Br. J. Cancer 106, 1713–1717 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  98. 98.

    Koelzer, V. H., Zlobec, I. & Lugli, A. Tumor budding in colorectal cancer–ready for diagnostic practice? Hum. Pathol. 47, 4–19 (2016).

    PubMed  Google Scholar 

  99. 99.

    Che, K., Zhao, Y., Qu, X., Pang, Z., Ni, Y., Zhang, T. et al. Prognostic significance of tumor budding and single cell invasion in gastric adenocarcinoma. Onco Targets Ther. 10, 1039–1047 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  100. 100.

    Tanaka, K., Shimura, T., Kitajima, T., Kondo, S., Ide, S., Okugawa, Y. et al. Tropomyosin-related receptor kinase B at the invasive front and tumour cell dedifferentiation in gastric cancer. Br. J. Cancer 110, 2923–2934 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  101. 101.

    Gabbert, H. E., Meier, S., Gerharz, C. D. & Hommel, G. Tumor-cell dissociation at the invasion front: a new prognostic parameter in gastric cancer patients. Int. J. Cancer 50, 202–207 (1992).

    CAS  PubMed  Google Scholar 

  102. 102.

    Kohler, I., Bronsert, P., Timme, S., Werner, M., Brabletz, T., Hopt, U. T. et al. Detailed analysis of epithelial-mesenchymal transition and tumor budding identifies predictors of long-term survival in pancreatic ductal adenocarcinoma. J. Gastroenterol. Hepatol. 30(Suppl 1), 78–84 (2015).

    CAS  PubMed  Google Scholar 

  103. 103.

    O'Connor, K., Li-Chang, H. H., Kalloger, S. E., Peixoto, R. D., Webber, D. L., Owen, D. A. et al. Tumor budding is an independent adverse prognostic factor in pancreatic ductal adenocarcinoma. Am. J. Surg. Pathol. 39, 472–478 (2015).

    PubMed  Google Scholar 

  104. 104.

    Karamitopoulou, E., Zlobec, I., Born, D., Kondi-Pafiti, A., Lykoudis, P., Mellou, A. et al. Tumour budding is a strong and independent prognostic factor in pancreatic cancer. Eur. J. Cancer 49, 1032–1039 (2013).

    CAS  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Contributions

All authors participated in the concept, drafting, editing and revision of this paper.

Corresponding author

Correspondence to Inti Zlobec.

Ethics declarations

Ethics approval and consent to participate

Images in Fig. 1 are from cases at the Institute of Pathology, University of Bern, approved by the ethics committee of the canton of Bern (KEK Bern). Patients have signed written informed consent.

Consent to publish

Not applicable.

Data availability

All data are included in this published article.

Competing interests

The authors declare no competing interests.

Funding information

Not applicable.

Additional information

Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zlobec, I., Berger, M.D. & Lugli, A. Tumour budding and its clinical implications in gastrointestinal cancers. Br J Cancer (2020). https://doi.org/10.1038/s41416-020-0954-z

Download citation